How rare is rhabdomyolysis from statin use, and which statins or factors increase the risk?
What the Evidence Shows
What we've found so far is that rhabdomyolysis from statin use is very rare. Our analysis of the available evidence suggests it occurs in about 1 to 2 out of every 10,000 people taking statins each year [1].
We looked at the data and found that serious muscle breakdown, known as rhabdomyolysis, is an uncommon side effect of statin therapy . While statins are widely used to manage cholesterol, this particular risk appears to be low overall. However, we’ve seen that the risk was higher with certain factors. One statin, cerivastatin, was linked to greater risk, but it’s no longer in use . Also, taking high-dose simvastatin may increase the chances of this condition, especially when combined with other medications or extreme physical exertion .
Our current analysis shows that not all statins carry the same level of risk, and dosage matters. The evidence we’ve reviewed leans toward the idea that both the type of statin and how it’s used can influence the likelihood of developing rhabdomyolysis . Still, because only one assertion supports this and no studies refute it, our understanding is limited. We don’t have enough data to compare all statins or to fully understand how other health factors or drug interactions affect risk.
Based on what we’ve reviewed so far, the chance of developing rhabdomyolysis while on statins is very low. But if you’re on a high dose of simvastatin or combining statins with intense exercise or other drugs, it may be worth discussing your individual risk with your healthcare provider.
Practical takeaway: For most people, the risk of serious muscle damage from statins is extremely low — about 1 in 5,000 to 10,000 per year — but certain statins and lifestyle factors may increase that risk.